分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Metal-coordinated nanomedicine for combined tumor therapy by inducing paraptosis and apoptosis

Rongrong Zheng, Linping Zhao, Xiayun Chen, Lingshan Liu, Yibin Liu, Xiantong Chen, Chang Wang, Xiyong Yu, Hong Cheng, Shiying Li

Journal:JOURNAL OF CONTROLLED RELEASE

IF:9.78

DOI:10.1016/j.jconrel.2021.06.021

PMID:34146614

Published:2021-06-17

research field:肿瘤学呼吸生物学生物化学

Abstract

Apoptosis resistance of tumor cells often results in chemoresistance and treatment failure in clinic. In this work, a Cu 2+ -coordinated morusin/doxorubicin biological organizer (designated as COMBO) is designed to combat cellular resistance to apoptosis for combined tumor therapy. By virtue of the coordination and π-π stacking effects, the self-assembled COMBO possesses nanometer particle size, narrow and homogenous graininess distribution as well as a good dispersion stability. Moreover, COMBO could be disassembled by glutathione (GSH) with an effective drug release and fluorescence recovery. Morusin-mediated paraptosis could induce extensive vacuolization through the dilation of endoplasmic reticulum (ER) and mitochondria, leading to non-apoptotic programmed cell death (PCD) regardless of the cellular resistance to apoptosis. Furthermore, the released doxorubicin prefers to locate in cell nucleus to cause cell apoptosis for combined chemotherapy. By the joint action of paraptosis and apoptosis, COMBO exhibits a great superiority over monotherapy in tumor inhibition with a low system toxicity. This study may open a window in the development of self-delivery nanomedicine for overcoming apoptosis resistance in tumor therapy.

本文使用的Yeasen产品

购物车
客服
转染试用